A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)

Study Overview

Primary objective:
  • Describe the characteristics of enrolled severe asthma patients
Secondary objectives:
  • Assess the control of asthma under dupilumab (Dupixent®) treatment until 1 year
  • Assess the clinical objectives of the asthma care
  • Assess comorbidities associated with Type 2 inflammation
  • Assess safety during the year of treatment

Study details

52 weeks

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Asthma
  • Age: Between 12 Years - 17 Years
  • Gender: All

Inclusion Criteria:
  • Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study
  • Adolescents ≥ 12 and < 18 years of age at the time of the initiation of Dupixent® treatment
Exclusion Criteria:
  • Adult participants ≥ 18 years of age
        The above information is not intended to contain all considerations relevant to a potential
        participation in a clinical trial.

Updated on 27 Mar 2024. Study ID: NCT05070663

Find a Study Location to Connect

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site